Conduit Pharmaceuticals Inc. has formally requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-1 effective by 4:30 p.m. Eastern Time on September 16, 2024. The request, made under Rule 461 of the Securities Act of 1933, as amended, was submitted through a correspondence from the company's CEO, David Tapolczay. The company's legal counsel, Todd Mason from Thompson Hine LLP, is the point of contact for the SEC to confirm the effectiveness of the Registration Statement or to address any inquiries.

Conduit Pharmaceuticals Inc. has formally requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-1 effective by 4:30 p.m. Eastern Time on September 16, 2024. The request, made under Rule 461 of the Securities Act of 1933, as amended, was submitted through a correspondence from the company's CEO, David Tapolczay. The company's legal counsel, Todd Mason from Thompson Hine LLP, is the point of contact for the SEC to confirm the effectiveness of the Registration Statement or to address any inquiries.